BRADLEY PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE-MONTH RESULTS.

FAIRFIELD, N.J.--(BUSINESS WIRE)--November 11, 1994--BRADLEY PHARMACEUTICALS, INC. (Nasdaq NMS: BPRXA), today announced that during the third quarter 1994, net sales of Bradley Pharmaceuticals, Inc. tripled to reach $2,988,132 as compared to net sales of $1,006, 610 during the same period in 1993. The strong sales performance during the summer, a time anticipated by management to be a relatively weak sales period due to seasonal product usage, has established a solid base to increase sales during the traditionally strong, upcoming fourth quarter 1994, and first quarter 1995. In addition to the traditional relatively weak sales of respiratory products during the summer months, the third quarter 1994 net loss of ($471,455) or ($0.07) per share, compared to a net loss of ($78,031) or ($0.04) per share in the previous year's third quarter, reflects a conscious investment in the future: the Company commitment to strengthen promotional programs, upgrade production facilities, develop new products, enhance managerial structure and accelerate international expansion.

Net sales for the nine-month period ending September 30, 1994 grew to $12,262,316, up approximately five-fold from the $2,651,635 reported in the corresponding nine months in 1993. Net income for the first nine months also significantly increased, jumping to $1,788,820 or $0.15 per share, on a fully diluted basis, a marked improvement over the loss of ($168,546), or ($0.08) per share incurred during the same nine month period in fiscal 1993.

Daniel Glassman, Chairman and Chief Executive Officer said: "During the first nine months of 1994 the significantly positive level of sales, net income and income per share confirm that meaningful progress continues to be made in implementing corporate strategy to develop Bradley as an increasingly growing and profitable force. Moreover, the management team is anticipating a strong fourth quarter in terms of sales and profits."

During third quarter 1994, a major effort was exerted to renovate and modernize the Doak Dermatologics facility, thereby increasing production in compliance with current Good Manufacturing Practices (cGMP). Bradley management is pleased to announce that at an independent environmental consultant's investigation has revealed that soil contaminants at the Doak manufacturing facility are below applicable state thresholds and that no evidence exists that such contaminants have affected the ground water. As a result, the Company has filed an application for removal from NYSDEC designation.

The Bradley management team also reported the expansion of overseas operations to 17 foreign countries, plus the strengthening of its infrastructure. The sales force was increased to 49 and internal staff in the areas of marketing, regulatory and research was significantly increased with the key additions of Peter Volk, Senior Vice President, Marketing and Sales; Margery Rothenberg, Director of Marketing; Albert Fleischner, Ph.D., Vice President Pharmaceutical Research and Development; and Bruce Caldwell, Vice President/Area Manager Southeast Asia. Bradley also announced the promotion of Alan V. Gallantar to V.P. Chief Financial Officer.

BRADLEY PHARMACEUTICALS markets and manufactures brandname over-the-counter and prescription pharmaceutical and health-related products, including respiratory, dermatologic, nutrition, personal hygiene, and internal medicine brands. Bradley Common A Shares and Bradley Class A, B, and D Warrants (BPRXW, BPRXZ, and BPRXL respectively) are traded on NASDAQ National Market System. -0-

                       BRADLEY PHARMACEUTICALS, INC.
                          CONDENSED CONSOLIDATED
                         STATEMENTS OF OPERATIONS
                               (UNAUDITED)

                         THREE MONTHS ENDED           NINE MONTHS ENDED
                           September 30,                September 30,
                          1994        1993            1994         1993

Net sales           $2,988,132   $1,006,610    $12,262,316   $2,651,635
Cost of sales        1,126,214      288,672      2,912,366      827,547
                     1,861,918      717,938      9,349,950    1,824,088

Selling, general
 and administrative
 expenses            2,479,807      764,544      6,482,677    1,924,308
Interest
 expense - net          93,058       31,425        474,383       68,326
                     2,572,865      795,969      6,957,060    1,992,634

(Loss) income before
  income taxes and
  minority interest   (710,947)     (78,031)     2,392,890     (168,546)
Income tax benefit
 (expense)             121,000            -       (726,000)           -

Minority interest in
  subsidiary's loss    118,492            -        121,930            -

Net (loss) income    $(471,455)    $(78,031)    $1,788,820    $(168,546)

Net (loss) income
  per common share    $  (0.07)    $  (0.04)     $    0.15     $  (0.08)

Weighted average
 number of common
 shares              6,400,000    2,179,500     16,300,000    2,179,500
    CONTACT:  Tiffany Ashley               Alan V. Gallantar
              Investor Relations           V.P. Chief Financial Officer
              South Coast Communications   Bradley Pharmaceuticals, Inc.
              714/252/8440                 201/882-1505    Ext. 266